GlassScriptPhysician profile
Basil M Griffin
NPI 1245206358
$4,957.10
in general payments reported to CMS, 2019-2025
32 companies · $599 in 2025
The $599 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $476 · 2020: $567 · 2021: $730 · 2022: $952 · 2023: $865 · 2024: $768 · 2025: $599.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,232.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,232.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $931.31 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $806.70 | 2019-2025 | Ozempic, Rybelsus |
| Janssen Pharmaceuticals, INC | $618.37 | 2019-2024 | Xarelto, Spravato |
| Boehringer Ingelheim Pharmaceuticals, INC. | $492.02 | 2019-2025 | Jardiance |
| Abbvie INC. | $455.39 | 2019-2025 | |
| Lilly USA, LLC | $261.58 | 2019-2023 | Emgality, Jardiance, Mounjaro |
| Novartis Pharmaceuticals Corporation | $159.39 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $159.18 | 2021-2024 | Austedo Xr, Austedo |
| Amarin Pharma, INC. | $156.56 | 2020-2021 | |
| Pfizer INC. | $131.80 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $91.30 | 2019-2021 | |
| Corcept Therapeutics | $84.17 | 2023-2025 | Korlym |
| Neurocrine Biosciences, INC. | $65.01 | 2020-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $64.79 | 2022 | |
| Amgen INC. | $64.13 | 2023-2024 | Repatha, Otezla |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $50.49 | 2025 | Voquezna |
| Merck Sharp & Dohme LLC | $36.43 | 2019 | |
| Abbott Laboratories | $32.71 | 2022 | |
| Allergan, INC. | $30.93 | 2020 | |
| Phadia US INC. | $28.68 | 2019-2021 | |
| Alexion Pharmaceuticals, INC. | $27.95 | 2025 | Strensiq |
| Insulet Corporation | $26.31 | 2020 | |
| Boston Scientific Corporation | $25.29 | 2024 | Watchman Flx |
| Genentech USA, INC. | $22.94 | 2022 | |
| Medtronic, INC. | $21.62 | 2024 | Intellis Adaptivestim |
| Acadia Pharmaceuticals INC | $21.56 | 2024 | Daybue |
| Alk-Abello, INC | $20.87 | 2023 | Grastek, Odactra, Ragwitek |
| Edwards Lifesciences Corporation | $17.23 | 2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Sanofi Pasteur INC. | $15.31 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.89 | 2020 | |
| Eisai INC. | $12.40 | 2021 | |
| Apria Healthcare LLC | $11.79 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Basil Griffin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.